X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (74) 74
humans (67) 67
female (58) 58
male (58) 58
adult (56) 56
middle aged (55) 55
gastroenterology & hepatology (53) 53
aged (40) 40
hepatitis c (35) 35
treatment outcome (34) 34
antiviral agents - therapeutic use (33) 33
drug therapy, combination (33) 33
hepatitis c virus (31) 31
hepatitis c, chronic - drug therapy (31) 31
gastroenterology and hepatology (27) 27
ribavirin (27) 27
interferon-alpha - therapeutic use (26) 26
hepacivirus - genetics (25) 25
hepatitis (24) 24
genotype (23) 23
interferon (23) 23
ribavirin - therapeutic use (23) 23
cirrhosis (20) 20
virus-infection (20) 20
young adult (19) 19
adolescent (18) 18
antiviral agents - administration & dosage (18) 18
antiviral agents - adverse effects (18) 18
patients (17) 17
hepatitis c - drug therapy (16) 16
recombinant proteins (16) 16
therapy (16) 16
infections (15) 15
polyethylene glycols - therapeutic use (15) 15
care and treatment (14) 14
drug therapy (14) 14
genotypes (14) 14
health aspects (14) 14
hepatitis c, chronic - virology (14) 14
interferon-alpha - adverse effects (14) 14
rna, viral - blood (13) 13
viral load (13) 13
abridged index medicus (12) 12
antiviral agents (12) 12
biological response modifiers (12) 12
clinical trials (12) 12
hcv (12) 12
interferon-alpha - administration & dosage (12) 12
ribavirin - adverse effects (12) 12
infectious diseases (11) 11
prospective studies (11) 11
ribavirin - administration & dosage (11) 11
virology (11) 11
viruses (11) 11
aged, 80 and over (10) 10
chronic hepatitis-c (10) 10
genotype & phenotype (10) 10
hepacivirus - drug effects (10) 10
plus ribavirin (10) 10
recombinant proteins - therapeutic use (10) 10
sustained virological response (10) 10
analysis (9) 9
chronic infection (9) 9
combination (9) 9
fibrosis (9) 9
germany (9) 9
infection (9) 9
liver (9) 9
research (9) 9
rna (9) 9
time factors (9) 9
adenine - analogs & derivatives (8) 8
direct-acting antivirals (8) 8
drug administration schedule (8) 8
efficacy (8) 8
genetic aspects (8) 8
hepatology (8) 8
medical research (8) 8
multivariate analysis (8) 8
polyethylene glycols - administration & dosage (8) 8
safety (8) 8
adenine - therapeutic use (7) 7
cohort studies (7) 7
combination therapy (7) 7
double-blind method (7) 7
follow-up studies (7) 7
polyethylene glycols - adverse effects (7) 7
recurrence (7) 7
sustained virologic response (7) 7
telaprevir (7) 7
alanine transaminase - blood (6) 6
biopsy (6) 6
double-blind (6) 6
drug resistance, viral (6) 6
hepatitis c, chronic - diagnosis (6) 6
liver diseases (6) 6
organophosphonates - therapeutic use (6) 6
recombinant proteins - adverse effects (6) 6
risk factors (6) 6
trial (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 6, pp. 497 - 506
Journal Article
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, pp. 553 - 553
The authors thank Ojha and Steyerberg for making a valid point regarding their manuscript. Indeed, defining analysis populations of real-life observational... 
Hepatitis | Motivation | Clinical trials | Population studies | Protocol | Hepatitis C | Antiviral drugs
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 55 - 63
Journal Article
ZEITSCHRIFT FUR GASTROENTEROLOGIE, ISSN 0044-2771, 10/2018, Volume 56, Issue 10, pp. 1300 - 1300
Journal Article
The American Journal of Gastroenterology, ISSN 0002-9270, 12/2008, Volume 103, Issue 12, pp. 3063 - 3070
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2008, Volume 359, Issue 23, pp. 2442 - 2455
Journal Article
Journal of hepatology, 08/2018, Volume 69, Issue 2, pp. 553 - 553
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 09/2006, Volume 44, Issue 3, pp. 675 - 684
Journal Article